At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Anxiolytics; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 05 Sep 2001 The compound is still in active development
- 17 Mar 1998 New profile
- 17 Mar 1998 Preclinical development for Anxiety disorders in USA (Unknown route)